Efficacy, safety and pharmacokinetics of artemether-lumefantrine dispersible tablet in the treatment of malaria in infants < 5 kg

• Conditions: The purpose of the study is to obtain efficacy, safety and pharmacokinetic (PK) data following treatment with artemether-lumefantrine dispersible tablet in infants < 5 kg of body weight (BW) with uncomplicated falciparum malaria.; MedDRA version: 18.1Level: PTClassification code 10025487Term: MalariaSystem Organ Class: 10021881 - Infections and infestations; Therapeutic area: Diseases [C] - Parasitic Diseases [C03]

• Registration Number: EUCTR2011-005852-33-Outside-EU/EEA
• Lead Sponsor: ovartis Pharma AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-04-11
• Last Update Posted: 18 April 2016

Recruitment & Eligibility

• Status: A
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

•Neonates / infants
•Body weight < 5 kg
•In cohort 1, infants aged > 28 days; in cohort 2, neonates of a term age 0 to = 28 days
•Microscopically confirmed diagnosis of acute uncomplicated Plasmodium falciparum malaria or mixed infections with an asexual Plasmodium falciparum parasitaemia of > 1,000 and < 100,000 parasites/µL

Are the trial subjects under 18? yes
Number of subjects for this age range: 30
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•Presence of severe malaria (according to World Health Organization definition)
•Presence of the following signs of a critical condition: apnea-bradycardia, sustained bradycardia, tachycardia, desaturation, hypotension, hypothermia; or other severely deteriorated general condition (based on IMCI criteria in sick infants)
•Presence of any clinically significant neurological condition
•Presence of clinically significant abnormality of the hepatic and renal systems
•Patients who sustained a significant blood volume loss (> 3% of calculated blood volume) in the past 30 days
•Patients unable to swallow or whose drinking is impaired
•Family history of congenital prolongation of the QTc interval or sudden death or with any other clinical condition known to be associated with prolongation of the QTc interval such as history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease
•Disturbances of electrolyte balance (e.g. hypokalaemia or hypomagnesaemia)
•Presence of any age-adjusted clinically or hematologically relevant laboratory and blood chemistry abnormalities
•Other protocol-defined inclusion/exclusion criteria may apply.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified